Adrenocortical Carcinoma Clinical Trials (2026): 18 Recruiting Interventional Studies

Last updated: March 10, 2026

Current Clinical Trial Landscape

About adrenocortical carcinoma (ACC):

ACC is a rare and aggressive cancer of the adrenal cortex. ~1-2 cases per million per year. Often diagnosed at advanced stages. Can be functional (hormone-producing) or non-functional.

Active research areas in 2026:

Standard of care: Resectable: surgery + adjuvant mitotane. Unresectable/metastatic: mitotane + etoposide/doxorubicin/cisplatin (EDP-M). Limited second-line options.

Recruiting Trials by Treatment Setting

Adjuvant Therapy

After surgery for resectable disease:

First-Line Metastatic

For newly diagnosed advanced disease:

Second-Line and Beyond

After progression on mitotane-based therapy:

Trials by Treatment Approach

Checkpoint Inhibitors

Immunotherapy trials for ACC:

Targeted Therapy

Regional Therapies

Antibody-Drug Conjugates

CAR-T Cell Therapy

Hormone-Based Approaches

View all 18 adrenocortical carcinoma trials on ClinicalTrials.gov →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Find ACC Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific stage and treatment history.

Find Matching Trials